Expansion and Innovation to
Meet Growing Customer Demand
A Major Investment in Bloomington, Indiana
In response to increasing customer needs for development services and clinical and commercial manufacturing capacity, Simtra BioPharma Solutions is carrying out a $250 million expansion of its Bloomington sterile manufacturing campus. This expansion is the latest in a series of strategic, long-term investments in both facilities and capabilities to ensure that Simtra can satisfy growing customer demand for injectable manufacturing support, particularly for GLP-1 drugs and oncology product candidates.
New Building,
Additional Production Lines
The expansion includes a 153,000-square-foot state-of-the-art building with 28,000 square feet of classified production area. It will house two high-speed, automated isolator syringe fill lines and a new high-speed isolator vial line for liquid or lyophilized vials. The building is slated to be GMP-ready in late 2027.
The expansion also includes the addition of a dedicated clinical line that will use existing facility infrastructure. Addition of this line paves the way for eventual commercial scale-up of early-stage products utilizing it. The new clinical line is expected to be ready for production by early 2026.
Besides enabling Simtra’s customers to deliver more doses of life-sustaining therapies to patients, the expansion is expected to create hundreds of new jobs in Bloomington.